Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose

Diabet Med. 2003 Sep;20(9):743-5. doi: 10.1046/j.1464-5491.2003.00993.x.


Aims: To investigate the effects of atorvastatin on glucose homeostasis, the basal and postprandial lipid profiles and the CRP levels (C reactive protein) in subjects with impaired fasting glucose (IFG).

Methods: Thirty-three subjects (22 men and 11 women) were included in our study. All displayed an IFG (fasting plasma glucose between 6.1 and 7.0 mmol/l) on at least two occasions during the last 6 months prior the study. They were randomly assigned to receive either 40 mg atorvastatin/day (n=16) or placebo (n=17) over 16 weeks, in a double-blind design. Before and after the end of the study all participants underwent on three consecutive days: a 75-g oral glucose tolerance test, a frequent sampling intravenous glucose tolerance test with Minimal Model analysis and a meal tolerance test (glucose, insulin and triglycerides). CRP was measured before and after the treatment period.

Results: CRP decreased significantly in the atorvastatin-treated group compared with the placebo group (percent change respect initial values; -42.3 %[-21.5 to - 63.1] and -9.6%[15.0 to -34.0], respectively, p<0.01). Atorvastatin treatment did not produce any change in oral glucose tolerance categories or induce any change in glucose and insulin response in OGTT. The statin produced a trend towards a significant improvement in insulin sensitivity as expressed by a change in Si from baseline to the end of treatment. Atorvastatin reduced the postprandial response of triglycerides to the meal test compared with placebo (19-26 % across the meal test, p<0.05) correlating with the amelioration observed in Si (-0.34, p<0.05; percentage changes).

Conclusion: Our results suggest that the use of statins in subjects with IFG seems to include other potentially beneficial actions in addition to their cholesterol-lowering effects.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Anticholesteremic Agents / therapeutic use*
  • Atorvastatin
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism*
  • C-Reactive Protein / drug effects
  • C-Reactive Protein / metabolism
  • Double-Blind Method
  • Fasting / blood
  • Female
  • Glucose Intolerance / blood
  • Glucose Intolerance / drug therapy*
  • Glucose Tolerance Test
  • Heptanoic Acids / therapeutic use*
  • Homeostasis / drug effects
  • Humans
  • Male
  • Middle Aged
  • Postprandial Period
  • Pyrroles / therapeutic use*
  • Triglycerides / blood*


  • Anticholesteremic Agents
  • Blood Glucose
  • Heptanoic Acids
  • Pyrroles
  • Triglycerides
  • C-Reactive Protein
  • Atorvastatin